Ovarian cancer patient Carol Giandonato admits to being apprehensive when her oncologist told her he wanted to make her cancer cells turn fluorescent green. “Am I going to glow in the dark? Will I be ...

Ovarian cancer is the 5 th leading cancer killer amongst women, and mortality rates have remained largely unchanged over the past three decades. The current standard of care is cytoreductive surgery, ...

A study found that the difficulty of surgery and the degree of cancer spread in the abdominal cavity can be predicted only by vaginal ultrasound performed before ovarian cancer surgery. The research ...

A new two-stage surgical approach for cancer prevention is highly acceptable among premenopausal women at high risk of ovarian cancer. A new two-stage surgical approach for cancer prevention is highly ...

—This study explores factors associated with complications and survival among women with epithelial ovarian cancer who undergo primary debulking surgery. Reviewed by Vrunda Bhavsar Desai, MD, FACOG, ...

An investigation of 24 women from the United Kingdom’s PROTECTOR trial has revealed that their concerns toward cancer risk and menopause affect their choice of surgery as treatment for ovarian cancer.

Cytalux is a fluorescent drug intended to assist surgeons in identifying ovarian cancer lesions. The Food and Drug Administration (FDA) has approved Cytalux™ (pafolacianine), an optical imaging agent, ...

Amanpour said she had surgery and is currently undergoing chemotherapy. When Christiane Amanpour, chief international anchor for CNN, announced Monday she has been diagnosed with ovarian cancer, she ...

Inherited changes in the tumor suppressor genes BRCA1 and BRCA2, raise lifetime risk substantially. For ovarian cancer, the National Cancer Institute estimates that 39 to 58 percent of women with ...

Christiane Amanpour is receiving treatment for ovarian cancer. The 63-year-old CNN anchor shared the stunning news with her viewers on June 14, after returning to work after a month-long absence from ...